About Dhruv Life Sciences
Dhruv Life Sciences is a company based in Hyderabad (India) founded in 2012. It operates as a B2B. The company has 2 employees. Dhruv Life Sciences offers products and services including Sterile Injectables and Biopharmaceuticals. Dhruv Life Sciences operates in a competitive market with competitors including Gland Pharma, Exela Pharma, Luoxin Pharmaceutical Group, Summit Biosciences and ApiJect, among others.
- Headquarter Hyderabad, India
- Employees 2
- SectorsHealthcare
- Website dhruvlifesciences.com
- Legal Name Dhruv Life Sciences Private Limited
- Date of Incorporation 19 Jan, 2012
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹6.67 Cr
FY 2019 · -17% YoY
- Net Loss-₹1.54 Cr
FY 2019 · -23% margin
- EBITDA-₹55.9 Lakh
FY 2019 · -8% margin
- Employee Count2
Associated legal entities of Dhruv Life Sciences
Dhruv Life Sciences operates through Dhruv Life Sciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2019) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Dhruv Life Sciences Private Limited CIN U24100KA2012PTC062151 | Active | 19 Jan 2012 | Bangalore, Karnataka | ₹6.7 Cr | 2 | 2 | View details |
Products & Services of Dhruv Life Sciences
Dhruv Life Sciences offers a comprehensive portfolio of products and services, including Sterile Injectables and Biopharmaceuticals.
Formulations for biopharmaceutical and lifesaving drug applications
Advanced drugs for healthcare and specialized treatments
Board of directors of Dhruv Life Sciences Private Limited (Dhruv Life Sciences)
Dhruv Life Sciences Private Limited is the primary company behind Dhruv Life Sciences. The board of Dhruv Life Sciences Private Limited currently have 2 directors; the longest-serving is Srivardhan Reddy Vanipanta, appointed in 2013. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Srivardhan Reddy Vanipanta DIN 06490332 | Director | 21 Mar 2013 | 13 yrs 6 mo | Dhruv Life Sciences Private Limited |
| Srinivas Penmitsa DIN 06880420 | Director | 15 Jan 2017 | 9 yrs 8 mo | Dhruv Life Sciences Private Limited |
Financials of Dhruv Life Sciences
Figures of Dhruv Life Sciences Private Limited, the primary company behind Dhruv Life Sciences, for FY 2019. Revenue was ₹6.67 Cr (-17% year on year). Net loss was -₹1.54 Cr (-23% margin). EBITDA was -₹55.9 Lakh (-8% margin). Revenue has grown at a compounded annual rate of -13% over three years and +1% over five years.
- ₹6.67 CrRevenue · FY 2019 · -17% YoY
- -₹1.54 CrNet loss · -23% margin
- -₹55.9 LakhEBITDA · -8% margin
- ₹4.00 CrPaid-up capital
- 2Employees (provident fund records)
- -13%Revenue CAGR, 3 years
- +1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Dhruv Life Sciences Private Limited are on its company page.
Detailed financial statements for Dhruv Life Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Dhruv Life Sciences
Dhruv Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Gland Pharma, Exela Pharma, Luoxin Pharmaceutical Group, Summit Biosciences and ApiJect, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| glandpharma.com | 1978 | Hyderabad, India | $208.59M | 4,319 | Generic injectable drugs are manufactured across therapeutic segments. | |
| exelapharma.com | 2005 | Lenoir, United States | $7.09M | 247 | Sterile injectable pharmaceuticals are manufactured alongside CDMO services. | |
| luoxin.cn | 2006 | Linyi, China | – | – | Developer and manufacturer of pharmaceutical products | |
| summitbiosciences.com | 2008 | Lexington, United States | – | – | Nasal spray drug products are developed, manufactured, and commercialized. | |
| apiject.com | 2015 | Stamford, United States | $111M | – | Medicine injectors are manufactured by ApiJect for medical applications. | |
| augustbio.com | 2017 | Nashville, United States | $88.6M | 86 | Diversified research services for clinical solutions are offered. | |
| vetter-pharma.com | 1950 | Ravensburg, Germany | – | – | CDMO specializing in aseptically prefilled syringe systems, cartridges and vials. | |
| incogbiopharma.com | 2020 | United States | $86.63M | – | Injectable drug products are manufactured by this biopharma CDMO. | |
| nitinlifesciences.com | 1994 | Karnal, India | – | 56 | CMO of small volume parenteral injectables |
Detailed competitors of Dhruv Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Dhruv Life Sciences
10 companies that operate in the same segment as Dhruv Life Sciences (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dhruv Life Sciences
Dhruv Life Sciences was founded in 2012.
Dhruv Life Sciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Dhruv Life Sciences has 2 employees.
The primary company behind Dhruv Life Sciences, Dhruv Life Sciences Private Limited, reported revenue of ₹6.67 Cr for FY 2019, down 17% year on year.
Dhruv Life Sciences Pvt. Ltd., based in Hyderabad, India, focuses on manufacturing and supplying biopharmaceuticals and specialized lifesaving injectable formulations. They emphasize advanced technologies for sterile injectables and aim to deliver excellence through innovation in the healthcare industry. The company serves as a one-stop solution for biopharmaceutical needs, targeting markets for lifesaving drugs with a commitment to quality and safety standards.
Dhruv Life Sciences's top competitors include Exela Pharma, Gland Pharma and Luoxin Pharmaceutical Group.
Dhruv Life Sciences offers Sterile Injectables and Biopharmaceuticals.
Dhruv Life Sciences operates through Dhruv Life Sciences Private Limited.
The legal entities of Dhruv Life Sciences currently have 2 directors, including Srivardhan Reddy Vanipanta, Srinivas Penmitsa.